- Home
- BTAI vs ANTX Comparison
BTAI vs ANTX Comparison
Compare BTAI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | ANTX |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | 37 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 31.2M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BTAI | ANTX |
|---|---|---|
| Price | $1.59 | $1.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $26.67 | $2.00 |
| AVG Volume (30 Days) | ★ 296.9K | 70.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $261.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $1.00 |
| 52 Week High | $8.08 | $1.49 |
Technical Indicators
Market Signals| Indicator | BTAI | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 45.59 |
| Support Level | $1.50 | $1.02 |
| Resistance Level | $1.72 | $1.16 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 24.53 | 50.00 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.